Introduction
============

Renal cell carcinoma (RCC) is one of the 10 most frequent types of cancer in women and men, accounting for ≤3% of all adult cancers. Types of RCC include clear cell (70%), papillary (10--15%), and chromophobe (5%) ([@b1-mmr-19-05-3485],[@b2-mmr-19-05-3485]). Clear cell RCC (ccRCC) is the main pathological type of primary renal tumor, which is associated with increased incidence, and high morbidity and mortality ([@b3-mmr-19-05-3485]). Through the use of abdominal imaging, patients with ccRCC are being more frequently identified ([@b4-mmr-19-05-3485]); however, this type of cancer is insensitive to radiotherapy and chemotherapy, and the 5-year survival rate of advanced stage patients following diagnosis is \<10% ([@b5-mmr-19-05-3485]). Several multi-center international studies have demonstrated that local or distant recurrence occurs in 20--40% of patients with localized tumors following nephrectomy ([@b6-mmr-19-05-3485]). Therefore, uncovering the underlying molecular mechanisms, and identifying effective diagnostic and prognostic molecular markers may help explore novel drug targets to control the proliferation, metastasis and drug resistance of ccRCC.

With the development of improved computer technology, high-throughput platforms have been widely applied for gene expression analysis. Microarray analysis and next-generation sequencing are increasingly utilized as essential tools in the field of medical oncology, with numerous clinical applications, including molecular classification of cancer, molecular diagnosis, prognosis prediction, patient stratification, tumor response prediction and novel drug target discovery ([@b7-mmr-19-05-3485],[@b8-mmr-19-05-3485]). Furthermore, various tumor-associated databases have been established, including the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). The GEO is an international public repository that contains a number of high-throughput microarray and next-generation sequencing datasets ([@b9-mmr-19-05-3485]). TCGA is a public database that includes 33 cancer types with matched clinical data, mRNA data and microRNA data ([@b10-mmr-19-05-3485],[@b11-mmr-19-05-3485]). The methods associated with bioinformatics analysis are constantly changing. The present study used GEO and TCGA databases to analyze mRNA alterations, and search for efficient diagnostic and prognostic biomarkers in ccRCC.

In the present study, four ccRCC datasets (GSE46699, GSE36895, GSE53000 and GSE53757) were downloaded from the GEO. Subsequently, the differentially expressed genes (DEGs) were screened by comparing adjacent normal kidney samples with ccRCC samples. The Robust Rank Aggregation (RRA) method was used to identify the statistically significant genes based on their ranks in each profile. Tumor-associated genetic alterations are known to result in tumorigenesis and the progression of ccRCC ([@b12-mmr-19-05-3485]). Therefore, the present study used the tumor-associated gene (TAG) database to identify the DEGs associated with cancer. Through this analysis, Erb-B2 receptor tyrosine kinase 4 (ERBB4), centrosomal protein 55 (CEP55) and vascular endothelial growth factor A (VEGFA) were identified as oncogenes. Furthermore, all three oncogenes were associated with the stage of ccRCC, whereas only CEP55 was associated with tumor prognosis according to Gene Expression Profiling Interactive Analysis (GEPIA). The oncogenic role of CEP55 in ccRCC remains unclear. TCGA data were used to analyze the expression levels, and potential diagnostic and prognostic values of CEP55 in ccRCC. Gene set enrichment analysis (GSEA) was also used to explore the underlying molecular mechanisms of CEP55 in ccRCC. The present study revealed that CEP55 may serve as a novel potential diagnostic and prognostic marker, and a potential therapeutic target for ccRCC.

Materials and methods
=====================

### Microarray and TCGA ccRCC data

The key phrase 'renal cell carcinoma' was used to search GEO datasets ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)), and the GSE46699, GSE36895, GSE53000 and GSE53757 microarray datasets were downloaded. The GSE46699 data were obtained using the GPL570 platform and included 63 adjacent normal kidney specimens and 67 ccRCC samples. The platform used to obtain the GSE36895 data was also GPL570, and this dataset consisted of 23 adjacent normal kidney samples and 29 ccRCC samples. The GSE53000 data were obtained using the GPL6244 platform and included six adjacent normal kidney samples and 28 ccRCC samples. The platform used to obtain the GSE53757 data was GPL570, and this dataset consisted of 72 adjacent normal kidney samples and 72 ccRCC samples. The data were calibrated, standardized and log~2~ transformed. TCGA contains DNA, RNA and protein data for human cancers, and can be used to analyze expression of these components in various types of cancer ([@b10-mmr-19-05-3485]). In the present study, the RNA-sequencing (RNA-seq) data of patients diagnosed with ccRCC were downloaded from TCGA on May 9th, 2018. The RNA-seq data based on the Illumina HiSeq RNA-seq platform included 74 adjacent normal kidney tissues and 536 ccRCC tissues. Additionally, there were 416 ccRCC patients with full clinical information including age, sex, histological type, Tumor-Node-Metastasis stage ([@b13-mmr-19-05-3485]) and overall survival (OS) time. The dataset information is presented in [Table I](#tI-mmr-19-05-3485){ref-type="table"} ([@b14-mmr-19-05-3485]--[@b17-mmr-19-05-3485]). R software (version 3.5.0, <http://www.r-project.org/>) was used for further analysis.

### Integration of microarray data

Limma package analysis ([@b18-mmr-19-05-3485]) was used to identify DEGs from the four microarray datasets. The RRA package ([@b19-mmr-19-05-3485]) from R language was used to analyze the list of up- and downregulated genes from the four profiles. The RRA method is used to compare the expression of different genes based on their ranks ([@b20-mmr-19-05-3485]). The higher the rank of a gene is in the selected datasets, the smaller its P-value is ([@b21-mmr-19-05-3485]).

### Functional annotation of DEGs

The present study downloaded all of the tumor-associated genes from the TAG database to assess whether the screened DEGs were associated with cancer ([@b22-mmr-19-05-3485]). Subsequently, GEPIA (<http://gepia.cancer-pku.cn/>) was applied to validate the different expression and prognostic values of the selected genes in ccRCC.

### Reverse transcription-polymerase chain reaction (RT-PCR)

A total of 15 paired fresh ccRCC tissues and adjacent tissues were obtained from patients (nine men and six women; age, 58±11 years). All patients underwent partial or radical nephrectomy at the Department of Urology, Ningbo Medical Centre Lihuili Hospital (Ningbo, China) between May and June 2018. Written informed consent was obtained from the patients and the present study was approved by the Ethics Committee of Ningbo Medical Centre Lihuili Hospital. RNA extraction, reverse transcription and amplification were conducted according to our previous study ([@b5-mmr-19-05-3485]). The primers used were as follows: CEP55, forward 5′-GCCATTGGGCGAGACCTACCT-3′, reverse 5′-GTTCGGGACTTCGCTCACCTT-3′; and GAPDH, forward 5′-ACAACTTTGGTATCGTGGAAGG-3′ and reverse 5′-GCCATCACGCCACAGTTTC-3′. GAPDH was used as the control. Data were presented as the means ± standard deviation from three experiments and were analyzed using the 2^−ΔΔCq^ method ([@b23-mmr-19-05-3485]).

### Diagnosis analysis

All 610 adjacent normal kidney and ccRCC tissue samples from TCGA dataset were randomly and equally divided into the training set (total n=305; number of adjacent normal kidney samples=37; and number of ccRCC samples=268) and the validation set (total n=305; number of adjacent normal kidney samples=37; and number of ccRCC samples=268). The training set was used to identify the potential diagnostic value of CEP55 expression, and the validation set was used to verify it. Area under the curve (AUC) values obtained from the receiver operating characteristic (ROC) curve analysis were utilized to assess the diagnostic effectiveness of CEP55. Generally, an AUC value of \>0.85 is considered to indicate diagnostic value ([@b24-mmr-19-05-3485]). The cut-off value is the detection value corresponding to the maximum value of the sum of sensitivity and specificity.

### GSEA

The c2.cp.kegg.gmt annotated gene set from the Java GSEA application was used to conduct the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis ([@b25-mmr-19-05-3485],[@b26-mmr-19-05-3485]). Normal P\<0.05 and false discovery rate q-value \<0.25 were chosen to indicate statistical significance.

### Statistical analysis

Student\'s t-test was used to analyze the significance between two groups. The associations between CEP55 and clinical factors were analyzed by χ^2^ test. Spearman\'s rank correlation coefficient was performed to access bivariate correlations. In addition, Kaplan-Meier analysis was used to assess OS and significance was determined using the log-rank test. Furthermore, the prognostic value of CEP55 in patients with ccRCC was evaluated by univariate and multivariate Cox regression analyses ([@b27-mmr-19-05-3485]). All tests were two-sided and P\<0.05 was considered to indicate a statistically significant difference. All statistical analyses were carried out using SPSS 23.0 (IBM, Corp., Armonk, NY, USA) and GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

### Microarray data resources and DEGs in ccRCC

The ccRCC expression microarray datasets GSE46699, GSE36895, GSE53000 and GSE53757 were downloaded from the GEO and were analyzed using limma package (adjusted P\<0.05, \|logFC\|\>1). A total of 271 DEGs were screened from the GSE46699; of which, 104 and 167 genes were up- and downregulated, respectively. In addition, 100 upregulated genes and 290 downregulated genes were obtained from the GSE36895 dataset. Furthermore, 532 upregulated genes and 649 downregulated genes, respectively, were detected from the GSE53000 dataset. Overall, there were 1,552 upregulated genes and 1,821 downregulated genes among the 3,373 DEGs screened from the *GSE53757* dataset. All of the DEGs from the four microarrays are presented in [Fig. 1](#f1-mmr-19-05-3485){ref-type="fig"}.

### Identification of DEGs in ccRCC by integrated bioinformatics

DEGs from each of the four ccRCC gene microarrays were identified based on the logFC value and then analyzed using the RRA method. A total of 223 DEGs were identified, including 78 upregulated genes and 145 downregulated genes according to the cut-off criterion of corrected P\<0.05 ([Table II](#tII-mmr-19-05-3485){ref-type="table"}). The heatmap presents the top 55 upregulated and 20 downregulated genes ([Fig. 2](#f2-mmr-19-05-3485){ref-type="fig"}).

### Functional annotation of DEGs

To determine whether the DEGs screened by RRA were associated with cancer, the present study searched the TAG database. The results revealed that 12 genes were TAGs; of which, three were oncogenes, including ERBB4, CEP55 and VEGFA; six were tumor suppressor genes, including ETS homologous factor (EHF), caveolin 1 (CAV1), S100 calcium binding protein A2 (S100A2), lysyl oxidase (LOX), caveolin 2 (CAV2) and transforming growth factor β induced (TGFBI); and three were uncertain, including solute carrier family 6 member 3 (SLC6A3), angiopoietin-like 4 (ANGPTL4) and fibroblast growth factor 9 (FGF9). Furthermore, all of the three oncogenes were associated with ccRCC stage ([Fig. 3](#f3-mmr-19-05-3485){ref-type="fig"}), whereas, of the three oncogenes, only CEP55 was associated with OS and disease-free survival according to GEPIA ([Fig. 4](#f4-mmr-19-05-3485){ref-type="fig"}).

### High expression of CEP55 in ccRCC

The molecular mechanisms, and the diagnostic and prognostic value of CEP55 in ccRCC, remain unclear. Therefore, the present study focused on the CEP55 gene for further study. As shown in [Fig. 5A](#f5-mmr-19-05-3485){ref-type="fig"}, CEP55 was upregulated in ccRCC tissues (n=536) but downregulated in adjacent normal kidney tissues (n=74) (P\<0.0001) based on the publicly available TCGA data. The present study further validated the overexpression of CEP55 in ccRCC tissues based on 71 paired ccRCC tissues (P\<0.001) ([Fig. 5B](#f5-mmr-19-05-3485){ref-type="fig"}). Furthermore, the mRNA expression levels of CEP55 were significantly upregulated in 15 paired clinical ccRCC tissues, as determined by RT-PCR analysis (P\<0.05; [Fig. 5C](#f5-mmr-19-05-3485){ref-type="fig"}). These results indicated that CEP55 was upregulated and may serve essential roles in the occurrence of ccRCC.

### Diagnostic value of CEP55 in ccRCC

To validate the potential diagnostic value of CEP55 mRNA, the training set was initially studied, and then the validation set was utilized for verification. ROC curves revealed that the AUC was 0.897 \[confidence interval (CI): 0.817--0.975\] in the training set and 0.947 (CI: 0.891--1.003) in the validation set for CEP55 ([Fig. 6](#f6-mmr-19-05-3485){ref-type="fig"}). Applying the cut-off value of 0.437, the specificity and sensitivity of CEP55 for the diagnosis of ccRCC patients vs. healthy controls was 92.7% (95% CI: 90.2--94.8%) and 86.5% (95% CI: 76.6--93.3%), respectively. These results confirmed that CEP55 could act as a diagnostic biomarker for ccRCC tissues.

### Association between CEP55 and clinical factors in ccRCC

To verify the association between CEP55 and clinical factors in ccRCC, the 416 ccRCC patients with full clinical information in TCGA dataset were further analyzed. The mRNA expression levels of CEP55 were strongly associated with sex (P=0.001), histological grade (P\<0.001), stage (P\<0.001), T classification (P\<0.001), N classification (P=0.007), M classification (P=0.002) and vital status (P\<0.001), but not with age (P=0.922; [Table III](#tIII-mmr-19-05-3485){ref-type="table"}). As determined by Spearman\'s analysis, CEP55 was correlated with sex (P=0.002), histological grade (P\<0.001), stage (P\<0.001), T classification (P\<0.001), N classification (P\<0.001), M classification (P\<0.001) and vital status (P\<0.001; [Table IV](#tIV-mmr-19-05-3485){ref-type="table"}). These results revealed a potential association between high CEP55 expression levels and the aggressive clinical characteristics of ccRCC, and also with sex.

### Association between high expression of CEP55 and poor prognosis

In order to further investigate the upregulation of CEP55 as a prognostic factor, 416 patients with ccRCC from TCGA were analyzed. Cox regression analysis was performed to determine whether CEP55 could be a potential predictive and prognostic factor. As shown in [Table V](#tV-mmr-19-05-3485){ref-type="table"}, high CEP55 expression was associated with a significantly increased risk of mortality in patients with ccRCC (P=0.006) when compared to those with low CEP55 expression, as determined by univariate Cox regression analysis. Multivariate Cox regression analysis also revealed that CEP55 expression (P=0.011) and M classification (P\<0.001) could be factors for predicting poor prognosis in ccRCC ([Table V](#tV-mmr-19-05-3485){ref-type="table"}). These results indicated that CEP55 expression may serve as a prognostic biomarker in ccRCC.

### GSEA

To evaluate KEGG pathway enrichment of CEP55 expression, GSEA was conducted based on the median expression of CEP55 in GSE53757. The top 10 relevant pathways in the CEP55 high-expression group are shown in [Table VI](#tVI-mmr-19-05-3485){ref-type="table"}. Taken together, the present GSEA results suggested that CEP55 may have multifaceted functions in immunization, cell adhesion, inflammation, the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway and cell proliferation in kidney carcinogenesis and progression ([Fig. 7](#f7-mmr-19-05-3485){ref-type="fig"}).

Discussion
==========

ccRCC is the most common subtype of RCC, which is associated with an increasing incidence, high metastatic potential and high mortality rates ([@b28-mmr-19-05-3485]). Over recent decades, the 5-year survival rate of ccRCC remains poor, despite in-depth study of the underlying mechanisms of occurrence, progression and metastasis ([@b29-mmr-19-05-3485],[@b30-mmr-19-05-3485]). Although numerous targeted and immunosuppressive drugs have emerged, drug resistance is still an urgent problem to be solved in the treatment of ccRCC. Therefore, highly specific and sensitive biomarkers, and elucidation of the underlying mechanism, are urgently required to reduce the mortality risk for patients with ccRCC.

Bioinformatics is a multidisciplinary field of research, and bioinformatics analysis is specifically utilized to identify candidate genes that aid the understanding of the genetic basis of diseases. In the present study, four gene expression profiles from the GEO were integrated and further analyzed via bioinformatics analysis. A total of 223 DEGs were screened, including 78 upregulated and 145 downregulated genes, by the RRA method. In addition, 12 genes that were associated with cancer were identified from DEGs according to the TAG database, including ERBB4, CEP55, VEGFA, EHF, CAV1, S100A2, LOX, CAV2, TGFBI, SLC6A3, ANGPTL4 and FGF9. Furthermore, only CEP55 was closely associated with ccRCC progression and prognosis as determined by GEPIA, an online method based on TCGA. Therefore, CEP55 has the potential to be a novel and valuable oncotarget protein in ccRCC.

CEP55, also known as FLJ10540, C10orf3 or URCC6, is located on chromosome 10q23.33 and serves an important role in cytokinesis ([@b31-mmr-19-05-3485],[@b32-mmr-19-05-3485]). As described previously, the protein localizes to the centrosome during interphase, dissociates from the centrosome in the M phase, and condenses to the midbody during cytokinesis ([@b33-mmr-19-05-3485]). However, centrosome amplification may participate in the origin of chromosomal instability during tumor development. High CEP55 expression results in disordered cytokinesis and an increased number of unstable binucleated cells; these are oncogenic characteristics in tumorigenesis ([@b34-mmr-19-05-3485],[@b35-mmr-19-05-3485]). Numerous studies have demonstrated that overexpression of CEP55 is associated with the pathological processes of several human malignances, including hepatocellular carcinoma ([@b36-mmr-19-05-3485]--[@b38-mmr-19-05-3485]), colon carcinoma ([@b39-mmr-19-05-3485]), breast cancer ([@b40-mmr-19-05-3485]--[@b42-mmr-19-05-3485]), lung cancer ([@b43-mmr-19-05-3485],[@b44-mmr-19-05-3485]), glioma ([@b45-mmr-19-05-3485]--[@b47-mmr-19-05-3485]), nasopharyngeal carcinoma ([@b48-mmr-19-05-3485]), oral cavity squamous cell carcinoma ([@b49-mmr-19-05-3485]), osteosarcoma ([@b50-mmr-19-05-3485]), head and neck cancer ([@b51-mmr-19-05-3485]), anaplastic thyroid carcinoma ([@b52-mmr-19-05-3485]), cervical cancer ([@b53-mmr-19-05-3485]), esophageal squamous cell carcinoma ([@b54-mmr-19-05-3485],[@b55-mmr-19-05-3485]), pancreatic cancer ([@b56-mmr-19-05-3485]) and prostate cancer ([@b57-mmr-19-05-3485],[@b58-mmr-19-05-3485]). In addition, high CEP55 expression in colorectal cancer downregulates the tumor susceptibility 101 gene in a post-transcriptional manner, and knockdown of CEP55 inhibits cell growth and increases apoptosis ([@b39-mmr-19-05-3485]). CEP55 is significantly upregulated in metastatic and recurrent prostate cancer when compared with localized and non-recurrent prostate cancer, and is associated with a poor biochemical recurrence-free survival time following radical prostatectomy ([@b58-mmr-19-05-3485]). High CEP55 and osteopontin expression levels in nasopharyngeal carcinoma tissues are markedly associated with advanced tumor stages and poor 5-year survival time, and result in the acceleration of cell growth and motility ([@b48-mmr-19-05-3485]). In addition, patients with hepatocellular carcinoma (HCC) and higher CEP55 expression have poorer survival ([@b37-mmr-19-05-3485]). CEP55 is associated with several oncogenic functions, including anchorage-independent growth, increased cell growth during starvation and induction of tumorigenesis in nude mice ([@b36-mmr-19-05-3485]). A previous mechanistic study of CEP55-mediated oncogenesis indicated that it functions though interactions with phosphoinositide-3 kinase ([@b7-mmr-19-05-3485]). Jones *et al* ([@b59-mmr-19-05-3485]) revealed that CEP55 is one of 18 genes that is positively correlated with renal cancer progression and is highly expressed in patients with RCC and metastasis. In addition, Luo *et al* ([@b60-mmr-19-05-3485]) analyzed three datasets, including GSE36895 and GSE46699; however, CEP55 was not revealed to be a DEG, this may be due to the different methods of analysis used compared with those used in the present study. The increased expression and carcinogenic properties of CEP55, and its association with clinical outcome in patients with ccRCC, remains unclear. Therefore, the present study used GEO and TCGA datasets to determine the expression and clinical significance of CEP55 in ccRCC.

In the present study, the results revealed that CEP55 was highly expressed in ccRCC tissues based on the GEO and TCGA datasets. In addition, the RT-PCR analysis demonstrated that the mRNA expression levels of CEP55 in 15 paired clinical ccRCC samples were consistent with the results obtained from open databases. This indicated that using open databases could support novel research design. The ROC curve analysis indicated that CEP55 may be a diagnostic biomarker for ccRCC with an AUC of 0.897 in the training set and 0.947 in the validation set. The specificity and sensitivity of CEP55 for the diagnosis of patients with ccRCC was 92.7 and 86.5%, respectively. In addition, CEP55 mRNA expression was markedly associated with clinical characteristics, including sex, histological grade, stage, T classification, N classification, M classification and OS time. The univariate and multivariate analyses also demonstrated that CEP55 may be an independent prognostic factor in patients with ccRCC. From these results, it was suggested that CEP55 may be considered a novel marker to predict the diagnosis and prognosis of ccRCC. To understand the mechanism underlying the effects of CEP55 on tumorigenesis, the present study performed KEGG analysis using GSEA. CEP55 was significantly enriched in pathways associated with immunization, cell adhesion, inflammation, JAK/STAT signaling and cell proliferation. A recent study demonstrated that CEP55 promotes HCC cell migration and invasion via physiological interactions with JAK2 and by regulating the JAK2/STAT3/matrix metalloproteinase signaling pathway ([@b37-mmr-19-05-3485]). Combined with the GSEA analysis, it was hypothesized that CEP55 may regulate cell proliferation and metastasis via the JAK/STAT signaling pathway.

In conclusion, the present study demonstrated that CEP55 may act as an oncogene that is highly expressed in ccRCC samples and associated with poor clinical outcomes; it may also be considered a diagnostic and prognostic biomarker for ccRCC. In addition, the results revealed that CEP55 may be associated with JAK2/STAT3 signaling pathway in tumor growth and metastasis. The present study has some limitations, as it was mainly based on public databases, and lacks *in vivo* and *in vitro* experiments. Tissue expression levels of CEP55, which can distinguish ccRCC patients from normal patients, only provides the potential diagnostic value of CEP55 in ccRCC and cannot be put into clinical application. Therefore, further study for the early detection of CEP55 in blood samples from patients with ccRCC should be implemented, and the function and mechanism of CEP55 in ccRCC should be verified in cell and animal experiments.
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![Volcano plots of the aberrantly expressed genes between ccRCC tissues and adjacent normal kidney tissues in the four datasets. (A) GSE46699, (B) GSE36895, (C) GSE53000 and (D) GSE53757 data. Red dots represent upregulated genes defined as logFC\>1.0 and adjusted P\<0.05. Green dots indicate downregulated genes based on logFC\<-1.0 and adjusted P\<0.05. Black dots represent mRNA expression with \|logFC\|\<1 and adjusted P\>0.05. ccRCC, clear cell renal cell carcinoma; FC, fold change.](MMR-19-05-3485-g00){#f1-mmr-19-05-3485}

![LogFC heatmap of each expression microarray. The color label indicates the different logFC values. Abscissa, Gene Expression Omnibus accession number; ordinate, gene names. FC, fold change.](MMR-19-05-3485-g01){#f2-mmr-19-05-3485}

![Associations between the expression of (A) ERBB4, (B) CEP55 and (C) VEGFA, and the stage of clear cell renal cell carcinoma, as determined by Gene Expression Profiling Interactive Analysis. CEP55, centrosomal protein 55; ERBB4, Erb-B2 receptor tyrosine kinase 4; VEGFA, vascular endothelial growth factor A.](MMR-19-05-3485-g02){#f3-mmr-19-05-3485}

![Kaplan-Meier survival curve analysis. Association between three oncogenes and overall and disease-free survival of clear cell renal cell carcinoma was determined by Gene Expression Profiling Interactive Analysis. Overall survival analysis: (A) ERBB4, (B) CEP55 and (C) VEGFA. Disease-free survival analysis: (D) ERBB4, (E) CEP44 and (F) VEGFA. CEP55, centrosomal protein 55; ERBB4, Erb-B2 receptor tyrosine kinase 4; HR, hazard ratio; VEGFA, vascular endothelial growth factor A.](MMR-19-05-3485-g03){#f4-mmr-19-05-3485}

![Overexpression of CEP55 in ccRCC. (A) CEP55 mRNA was upregulated in 536 ccRCC tissues when compared with 74 adjacent normal kidney tissues according to TCGA data. (B) CEP55 mRNA expression was significantly increased in 71 paired ccRCC tissues compared with adjacent normal tissues, as determined using TCGA data. (C) Reverse transcription-polymerase chain reaction analysis of CEP55 expression in 15 paired ccRCC tissues and their adjacent normal tissues. Data are representative of three experiments. \*P\<0.05. CEP55, centrosomal protein 55; ccRCC, clear cell renal cell carcinoma; TCGA, The Cancer Genome Atlas.](MMR-19-05-3485-g04){#f5-mmr-19-05-3485}

![Receiver operating characteristic curves of centrosomal protein 55 in the (A) training and (B) validation sets. AUC, area under the curve.](MMR-19-05-3485-g05){#f6-mmr-19-05-3485}

![KEGG pathways associated with high CEP55 expression. (A) Natural killer cell-mediated cytotoxicity, (B) chemokine signaling pathway, (C) cell adhesion molecules CAMs, (D) cytokine-cytokine receptor interaction, (E) JAK/STAT signaling pathway and (F) cell cycle. CEP55, centrosomal protein 55; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; NES, normal enrichment score; NOM, normal.](MMR-19-05-3485-g06){#f7-mmr-19-05-3485}

###### 

Summary of GEO and TCGA clear cell renal cell carcinoma datasets.

  Author, year                  Sample   GEO no.    Platform   Normal   Tumor   (Refs.)
  ----------------------------- -------- ---------- ---------- -------- ------- -------------------------
  Eckel-Passow *et al*, 2014    ccRCC    GSE46699   GPL570     63       67      ([@b14-mmr-19-05-3485])
  Peña-Llopis *et al*, 2012     ccRCC    GSE36895   GPL570     23       29      ([@b15-mmr-19-05-3485])
  Gerlinger *et al*, 2014       ccRCC    GSE53000   GPL6244    6        28      ([@b16-mmr-19-05-3485])
  von Roemeling *et al*, 2014   ccRCC    GSE53757   GPL570     72       72      ([@b17-mmr-19-05-3485])
  TCGA                          ccRCC    --         --         74       536     --

GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.

###### 

DEGs in clear cell renal cell carcinoma, as determined using the Robust Rank Aggregation method.

  DEGs            Gene names
  --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated     DIRAS2, MCAM, IGFBP3, FABP5, C1QA, LAMA4, TNFAIP6, NDUFA4L2, VCAN, CXCR4, CEP55, CD163, NPTX2, IDO1, ITGB2, GAL3ST1, CTHRC1, C1QC, HK2, VEGFA, SEMA5B, APOLD1, DNAH11, SCARB1, RASSF2, LOX, AHNAK2, COL23A1, GAS2L3, NETO2, FABP7, CCL18, CAV1, LINC00462, CXCL13, TGFBI, PLK2, ANGPTL4, DDIT4, INHBB, QRFPR, LAPTM5, BHLHE41, CYP2J2, SPAG4, C5orf46, LPCAT1, PNMA2, CP, ADM, HILPDA, LINC00887, LOXL2, PLA2G7, NNMT, CA9, C1QB, APOC1, ADAMDEC1, ENPP3, EGLN3, ENO2, TLR3, FCGR1B, TMEM45A, PCSK6, CD70, KISS1R, CENPK, CAV2, SLC6A3, RGS1, VWF, FN1, ANGPT2, ST8SIA4, C3, ESM1
  Downregulated   CYP17A1, SMIM24, NPHS2, ERBB4, ESRP1, PSAT1, RALYL, SLC4A9, TFCP2L1, XPNPEP2, SPINK1, SCNN1B, ALB, PLG, SLC4A1, SLC12A1, ALDOB, CNTN3, ERP27, ALDH8A1, TSPAN8, UPP2, FCAMR, LOC284578, SLC22A8, KL, KCNJ10, EHF, SLC13A3, CYP8B1, AZGP1, ALDH6A1, HPD, SLC7A13, SLC22A6, EFHD1, SUCNR1, TMEM213, AFM, ACPP, LOC100505985, RAB25, HPGD, CRHBP, FXYD4, HRG, ASS1, AQP2, DAO, SLC16A9, DNER, C16orf89, DCXR, EGF, PVALB, RHCG, UMOD, FOXI1, CYP4A11, FAM3B, ABAT, HOGA1, ATP6V0D2, LINC00645, TMEM52B, NRK, PTH1R, TMEM207, TMEM174, GGT6, CALB1, DIO1, KCNJ1, MIOX, TUBB2B, SLC12A3, ATP6V1G3, CRYAA, RNF212B, SCNN1A, HSD11B2, TMEM178A, OGDHL, TUBAL3, SOSTDC1, TYRP1, S100A2, ENPP6, MAL, PCP4, DEFB1, FGF1, ATP6V1B1, SERPINA5, DUSP9, SFRP1, VTCN1, TFAP2B, GLDC, GPC5, FBP1, CLDN8, CLCNKB, SLC7A8, PPP1R1A, SLC22A12, PIPOX, CLDN16, PLPPR1, MAL2, CYP2B6, NPHS1, CYP27B1, DDC, TMPRSS2, PRODH2, FABP1, CYP4F3, CDH16, PCK1, MTTP, SLC5A2, SLC22A7, ESRRG, SLC26A4, SLC47A2, FAM151A, ADH1C, EPCAM, KNG1, CYP4F2, ADH6, PCSK1N, MT1H, ATP6V0A4, SLC34A1, MUC15, HEPACAM2, RP11-999E24.3, FGF9, DPEP1, AGPAT9, SOST, LRRC19, ACSF2

DEGs, differentially expressed genes.

###### 

Association between CEP55 expression and clinical characteristics of patients with clear cell renal cell carcinoma in The Cancer Genome Atlas dataset.

                                    CEP55         
  -------------------- ------------ ------- ----- ---------
  Age (years)                                     0.922
    ≥60                215 (51.7)   107     108   
    \<60               201 (48.3)   101     100   
  Sex                                             0.001
    Male               264 (63.5)   116     148   
    Female             152 (36.5)   92      60    
  Histological grade                              
    G1                 10 (2.4)     9       1     \<0.001
    G2                 201 (48.3)   116     85    
    G3                 160 (38.5)   70      90    
    G4                 45 (10.8)    13      32    
  Stage                                           \<0.001
    I                  252 (60.6)   151     101   
    II                 53 (12.7)    25      28    
    III                69 (16.6)    21      48    
    VI                 42 (10.1)    11      31    
  T classification                                \<0.001
    T1                 256 (61.5)   152     104   
    T2                 61 (14.7)    28      33    
    T3                 92 (22.1)    28      64    
    T4                 7 (1.7)      0       7     
  N classification                                0.007
    N0                 402 (96.6)   206     196   
    N1-2               14 (3.4)     2       12    
  M classification                                0.002
    M0                 375 (90.1)   197     178   
    M1                 41 (9.9)     11      30    
  Vital status                                    
    Alive              308 (74)     170     138   \<0.001
    Deceased           108 (26)     38      70    

Data were analyzed using the χ^2^ test. CEP55, centrosomal protein 55; M, metastasis; N, node; T, tumor.

###### 

Correlation of CEP55 mRNA expression with clinical characteristics, as determined by Spearman analysis.

                       CEP55 expression level   
  -------------------- ------------------------ ---------
  Age                  −0.077                   0.119
  Sex                  0.152                    0.002
  Histological grade   0.271                    \<0.001
  Stage                0.326                    \<0.001
  T classification     0.311                    \<0.001
  N classification     0.224                    \<0.001
  M classification     0.228                    \<0.001
  Vital status         0.217                    \<0.001

CEP55, centrosomal protein 55; M, metastasis; N, node; T, tumor.

###### 

Univariate and multivariate Cox regression analyses of various prognostic factors in patients with clear cell renal cell carcinoma.

                       Univariate analysis   Multivariate analysis                                    
  -------------------- --------------------- ----------------------- -------------- --------- ------- --------------
  CEP55 expression     0.006                 1.755                   1.179--2.612   0.011     1.683   1.127--2.513
  Age                  0.002                 1.919                   1.276--2.884   --        --      --
  Sex                  0.450                 0.861                   0.583--1.270   --        --      --
  Histological grade   \<0.001               2.429                   1.847--3.195   --        --      --
  Stage                \<0.001               2.000                   1.700--2.353   --        --      --
  T classification     \<0.001               2.133                   1.744--2.610   --        --      --
  N classification     \<0.001               4.184                   2.104--8.320   --        --      --
  M classification     \<0.001               6.005                   3.912--9.216   \<0.001   5.880   3.823--9.043

CEP55, centrosomal protein 55; CI, confidence interval; HR, hazard ratio; M, metastasis; N, node; T, tumor.

###### 

KEGG pathways associated with high CEP55 expression, as determined by gene set enrichment analysis.

  KEGG pathway                                Size   ES     NES    NOM P-value   FDR q-value
  ------------------------------------------- ------ ------ ------ ------------- -------------
  Natural killer cell-mediated cytotoxicity   127    0.66   2.28   \<0.001       \<0.001
  Chemokine signaling pathway                 180    0.59   2.17   \<0.001       0.002
  Cell adhesion molecules CAMs                128    0.56   2.11   \<0.001       0.005
  Cytokine-cytokine receptor interaction      246    0.56   2.1    \<0.001       0.003
  Antigen processing and presentation         73     0.64   2.06   \<0.001       0.004
  Toll-like receptor signaling pathway        96     0.6    2.03   \<0.001       0.004
  T cell receptor signaling pathway           107    0.57   2.02   0.004         0.004
  B cell receptor signaling pathway           74     0.57   1.97   0.004         0.006
  JAK/STAT signaling pathway                  149    0.51   1.95   \<0.001       0.006
  Cell cycle                                  122    0.54   1.91   \<0.001       0.010

CEP55, centrosomal protein 55; ES, enrichment score; FDR, false discovery rate; GSEA, gene set enrichment analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; NES, normal enrichment score; NOM, normal.

[^1]: Contributed equally
